M. Heek, C. France, D. Compton, R. Mcleod, N. Yumibe, K. Alton, E. Sybertz, H. Davis (1997)
In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.The Journal of pharmacology and experimental therapeutics, 283 1
(2001)
Biliary excretion and pharmacokinetics of ezetimibe in rats and dogs (Abstract)
-hydroxyphenyl)-2-azetidinone, by liver and kidney slices (Abstract)
W. Fuchs, A. Nieciecki, K. Molz, G. Popescu, A. Weil, M. Barkworth, S. Gay, A. Laicher, F. Stanislaus (1998)
[The effect of bile secretion on the pharmacokinetics of a theophylline sustained-release preparation].Arzneimittel-Forschung, 48 5A
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
T. Kosoglou, I. Meyer, E. Veltri, P. Statkevich, Bo Yang, Yali Zhu, L. Mellars, S. Maxwell, J. Patrick, D. Cutler, V. Batra, M. Affrime (2002)
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatinBritish Journal of Clinical Pharmacology, 54
Jennifer Marcelino, K. Feingold (1996)
Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.The American journal of medicine, 100 6
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
Kosoglou (2000)
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin (Abstract).Atherosclerosis, 151
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
Tuart, C. M., Obbe, Hristopher, I. G., Eter, M. W., Acfarlane, Ames, M. H, Illop, P. J, Ackard (2000)
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
(2000)
Effect of ezetimibe (SCH 58235) on the activity of drug-metabolizing enzymes in vivo
M. Heek, C. Farley, D. Compton, L. Hoos, K. Alton, E. Sybertz, H. Davis (2000)
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 129
(2000)
Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): pooled analysis of two phase II studies (Abstract)
Farkad Ezzet, Gopal Krishna, David Wexler, P. Statkevich, T. Kosoglou, Vijay Batra (2001)
A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.Clinical therapeutics, 23 6
(1999)
Metabolism of SCH 58235 in the human, rat and dog (Abstract)
D. Wood, G. Backer, I. Graham, P. Poolewilson, K. Pyörälä, J. Shepherd, A. Zanchetti, P. Hamań, K. Linhartová, J. Šimon, M. Hrnčárek, P. Lupínek, T. Marek, A. Kemppainen, H. Koukkunen, S. Lehto, R. Lehto, S. Danet, R. Domanievicz, B. Lemaire, M. Lenoir, M. Montaye, P. Amouyel, U. Broxtermann, M. Heimbach, A. Liese, U. Keil, A. Enbergs, G. Breithardt, H. Scheld, P. Kleinekatthofer, S. Borbás, M. Podmaniczky, E. Östör, A. Jánosi, A. Bradák, Ab Kenez, C. Leprotti, G. Ambrosio, D. Vanuzzo, L. Pilotto, P. Stritoni, A. Pedrocco, F. Perissinotto, P. Zardin, A. Gallo, L. Rossi, F. Post, J. Deckers, A. Deboer, Veerhoek, E. Stockx, R. Vandeberg, W. Remme, R. vanVliet, K. Marn, Salapure, J. Turk, G. Paluzié, I. Pérez, T. Puig, C. Varas, S. Sans, A. Deluna, F. López, P. Monrás, T. Bowker, J. Ingham, N. Mclennan, B. Schofield, D. Bacquer, D. James, J. Deckers, F. Gutzwiller (1997)
A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results.European Heart Journal, 18
(1999)
The effect of gender on the pharmacokinetics of SCH 58235 , a cholesterol absorption inhibitor ( Abstract )
S. Grundy, D. Bilheimer, A. Chait, L. Clark, M. Denke, R. Havel, W. Hazzard, S. Hulley, D. Hunninghake, R. Kreisberg, P. Kris-Etherton, J. Mckenney, Michael Newman, E. Schaefer, B. Sobel, C. Somelofski, M. Weinstein, H. Brewer, J. Cleeman, K. Donato, N. Ernst, J. Hoeg, B. Rifkind, J. Rossouw, C. Sempos, J. Gallivan, M. Harris, L. Quint-Adler (1993)
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 269 23
M. Gibaldi, D. Perrier (1982)
Noncompartmental Analysis Based on Statistical Moment Theory
J. Feely, P. McGettigan, A. Kelly (2000)
Growth in use of statins after trials is not targeted to most appropriate patientsClinical Pharmacology & Therapeutics, 67
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
E. Sybertz, H. Davis, B. Salisbury, R. Burrier, J. Clader, D. Burnett (1994)
SCH 48461, a novel inhibitor of cholesterol absorptionAtherosclerosis, 109
Zhu (2000)
Effect of ezetimibe (SCH 58235) on the activity of drug-metabolizing enzymes in vivo (Abstract).Clin Pharmacol Ther, 67
(1997)
EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.European heart journal, 18 10
T. Pearson, I. Laurora, H. Chu, S. Kafonek (2000)
The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Archives of internal medicine, 160 4
Abstract no. 45, Societé Francaise de Pharmacologie
J. Tuomilehto, G. Vidgrén, L. Toivanen, E. Tuomilehto-Wolf, K. Kohtamäki, J. Stengård, P. Zimmet, I. Mackay, M. Rowley, P. Koskela (1994)
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 343
S. Rosenblum, T. Huynh, A. Afonso, H. Davis, N. Yumibe, J. Clader, D. Burnett (1998)
Discovery of 1‐(4‐Fluorophenyl)‐(3R)‐ [3‐(4‐fluorophenyl)‐(3S)‐hydroxypropyl] ‐(4S)‐(4‐hydroxyphenyl)‐2‐azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption.ChemInform, 29
(2000)
The cholesterol absorption inhibitor ezetimibe (SCH 58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis (Abstract)
Brian Salisbury, Harry Davis, R. Burrier, D. Burnett, G. Boykow, Mary Caplen, Anthony Clemmons, D. Compton, L. Hoos, D. McGregor, Robin Schnitzer-Polokoff, April Smith, Blair Weig, Deborah Zilli, J. Clader, Edmund Sybertz (1995)
Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.Atherosclerosis, 115 1
Drug Metabolism and Disposition – Pubmed
Published: May 17, 2002
Access the full text.
Sign up today, get DeepDyve free for 14 days.